Additional file 1 of Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial

Additional file 1: Figure S1. Distribution Analysis of NE Activity in WBCs Collected Over the Trial Duration. NE activity from WBCs is shown in a quantile-quantile plot of measured values versus predicted standard normal distribution values, in a distribution plot, and in a relative frequency histogram plot. The height of the outlined box in panel B indicates the mean value for each arm. Median values for WBC NE are 5772, 4947, 3392 and 4776 ng/mL for placebo, 10 mg brensocatib, 25 mg brensocatib and all arms combined, respectively. Figure S2. Distribution Analysis of Sputum NE Activity Collected Over the Trial Duration. NE activity in sputum is shown in a quantile-quantile plot of measured values versus predicted standard normal distribution values, in a distribution plot, and in a relative frequency histogram plot. The bar in panel B indicates the mean NE activity for each arm. Median activity values for each group in the analysis are 3.32, 2.21, 1.50 and 2.30 log (ng/mL) for sputum NE for placebo, 10 mg brensocatib, 25 mg brensocatib and all arms combined, respectively. When converted back from log transformation, the median values are 2089, 162, 32 and 200 ng/mL for sputum NE, respectively. Figure S3. Distribution Analysis of Sputum PR3 Activity Collected Over the Trial Duration. PR3 activity in sputum is shown in a quantile-quantile plot of measured values versus predicted standard normal distribution values, in a distribution plot, and in a relative frequency histogram plot. The bar in panel B indicates the mean PR3 activity for each arm. Median activity values are 3.63, 3.60, 3.46, and 3.55 log (ng/mL) for sputum PR3 for placebo, 10 mg brensocatib, 25 mg brensocatib and all arms combined, respectively. When converted back from log transformation, the median values are 4266, 3981, 2884 and 3548 ng/mL for sputum PR3, respectively. Figure S4. Distribution Analysis of Sputum CatG Activity Collected Over the Trial Duration. CatG activity in sputum is shown in a quantile-quantile plot of measured values versus predicted standard normal distribution values, in a distribution plot, and in a relative frequency histogram plot. The bar in panel B indicates the mean CatG activity for each arm. Median activity values are 1.29, 0.29, 0.29 and 0.29 log (ng/mL) for sputum PR3 for placebo, 10 mg brensocatib, 25 mg brensocatib and all arms combined, respectively. When converted back from log transformation, the median values are 19, 1.9, 1.9 and 1.9 ng/mL for sputum PR3, respectively.